Aveo Capital Partners’s Oruka Therapeutics ORKA Stock Holding History

Aveo Capital Partners’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-7,976	Closed	-$661K	–	203
2019 Q2	$661K	Buy	7,976 +7,544	+1,746%	+$677K	0.29%	76
2019 Q1	$35K	Hold	432	–	–	0.02%	166
2018 Q4	$31K	Hold	432	–	–	0.02%	129
2018 Q3	$58K	Hold	432	–	–	0.03%	138
2018 Q2	$52K	Hold	432	–	–	0.02%	138
2018 Q1	$47K	Hold	432	–	–	0.02%	140
2017 Q4	$126K	Hold	432	–	–	0.04%	139
2017 Q3	$107K	Sell	432 -2	-0.5%	-$711	0.04%	131
2017 Q2	$225K	Buy	434 +210	+94%	+$110K	0.08%	109
2017 Q1	$123K	Sell	224 -849	-79%	-$474K	0.05%	124
2016 Q4	$661K	Buy	+1,073	New	+$571K	0.19%	82

Other funds holding ORKA

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Quantamental Technologies White Plains, New York $106M AUM 22.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Aveo Capital Partners's ORKA Position: Q3 2019 in Review

Aveo Capital Partners sold out of Oruka Therapeutics (ORKA) in Q3 2019, closing a stake of 7,976 shares — an estimated $661K sold.

Aveo Capital Partners first reported a position in ORKA in Q4 2016 and held it in 11 quarters. The position peaked at $661K in Q2 2019. 12 funds tracked by Wall St. Rank hold ORKA as of Q3 2019.

Aveo Capital Partners reported no remaining Oruka Therapeutics position as of Q3 2019 after selling out during the quarter.
Aveo Capital Partners sold 7,976 Oruka Therapeutics shares in Q3 2019, an estimated $661K.
Aveo Capital Partners first reported a position in Oruka Therapeutics in Q4 2016 and held it in 11 quarters.
Aveo Capital Partners's Oruka Therapeutics position peaked at $661K in Q2 2019.
12 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2019.

Based on Aveo Capital Partners's 13F filing for Q3 2019, filed 7 Nov 2019.